Literature DB >> 11062596

Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

K A Payne1, S Esmonde-White.   

Abstract

Real-world adherence to pharmacotherapy cannot be studied in the confines of the traditional clinical trial. Thus, to better understand adherence to antihypertensive medication in actual practice, a literature search was conducted to identify observational database studies of the use of antihypertensive medication. Ten studies were identified: half studied adherence patterns after initial prescriptions to patients with a new diagnosis of hypertension, and the others evaluated antihypertensive medication use in a mix of patients with newly diagnosed or chronic hypertension. Overall, results demonstrated that adherence to treatment for hypertension in the first year is very poor. In addition, it appears that initial treatment with newer classes of drugs, such as angiotensin II antagonists, angiotensin converting enzyme inhibitors, and calcium channel blockers favors treatment adherence. This review also highlights and discusses possible under-lying factors contributing to these results and implications for physicians.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062596     DOI: 10.1007/s11906-996-0035-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  51 in total

Review 1.  Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?

Authors:  J M Wright; C H Lee; G K Chambers
Journal:  CMAJ       Date:  1999-07-13       Impact factor: 8.262

2.  Evidence-based medicine. A new approach to teaching the practice of medicine.

Authors: 
Journal:  JAMA       Date:  1992-11-04       Impact factor: 56.272

3.  Economic impact of cardiovascular disease in Canada.

Authors:  B Chan; P Coyte; C Heick
Journal:  Can J Cardiol       Date:  1996-10       Impact factor: 5.223

4.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

5.  Patients' experiences of antihypertensive drugs in routine use: results of a Danish general practice survey.

Authors:  N J Borrild
Journal:  Blood Press Suppl       Date:  1997

6.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

7.  Measuring patient compliance in antihypertensive therapy--some methodological aspects.

Authors:  H Enlund
Journal:  J Clin Hosp Pharm       Date:  1982-03

8.  Effect of pharmaceutical formulation for antihypertensive therapy on health service utilization.

Authors:  T L Skaer; D A Sclar; L M Robison; A Chin; M A Gill; M P Okamoto; R K Nakahiro
Journal:  Clin Ther       Date:  1993 Jul-Aug       Impact factor: 3.393

9.  The determinants of hypertension awareness, treatment, and control in an insured population.

Authors:  D H Stockwell; S Madhavan; H Cohen; G Gibson; M H Alderman
Journal:  Am J Public Health       Date:  1994-11       Impact factor: 9.308

10.  Comparison of prescription and medical records in reflecting patient antihypertensive drug therapy.

Authors:  D B Christensen; B Williams; H I Goldberg; D P Martin; R Engelberg; J P LoGerfo
Journal:  Ann Pharmacother       Date:  1994-01       Impact factor: 3.154

View more
  23 in total

1.  The value of industry-sponsored studies of initial antihypertensive therapies.

Authors:  J J Caro; K Payne
Journal:  CMAJ       Date:  2001-06-26       Impact factor: 8.262

Review 2.  Compliance and persistence with newer antihypertensive agents.

Authors:  William C Gerth
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

3.  Initial treatment of hypertension and adherence to therapy in general practice in Italy.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Antonio Vargiu; Giacomo Chiabrando; Maria Chiara Silvani; Domenico Motola; Giulia Sangiorgi Cellini; Alberto Vaccheri; Fabrizio De Ponti; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2005-08-05       Impact factor: 2.953

4.  Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study.

Authors:  Jun Lu; Liming Lee; Weihua Cao; Siyan Zhan; Guoying Zhu; Liqiang Dai; Yonghua Hu
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

5.  Initial phase of chronic medication use; patients' reasons for discontinuation.

Authors:  J G Hugtenburg; A Th G Blom; S U Kisoensingh
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

6.  Adherence level of antihypertensive agents in coronary artery disease.

Authors:  Sylvie Perreault; Alice Dragomir; Louise Roy; Michel White; Lucie Blais; Lyne Lalonde; Anick Bérard
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

Review 7.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Nonadherence in patients with hypertensive emergency or hypertensive urgency.

Authors:  Bernhard K Krämer; Robert M Krämer; Urs Benck; Bernd Krüger
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-05       Impact factor: 3.738

9.  The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants.

Authors:  K A Payne; J J Caro; W L Daley; Z M Khan; K J Ishak; K Stark; D Purkayastha; J Flack; E Velázquez; S Nesbitt; D Morisky; R Califf
Journal:  Int J Clin Pract       Date:  2008-07-21       Impact factor: 2.503

Review 10.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.